Omega Diagnostics Share Discussion Threads

[weatherman] 31/10/2015 15:36

Is that why Barclays are refusing to trade...? Hasn't this created a false market where some brokers are dealing and others not ?

[aldi1] 30/10/2015 20:09

Something to do with a previous customer and fraud with dealing with this company.
Not exactly sure,my broker was informed by corporate after the deal was done.
!!?

[barrywhit] 30/10/2015 18:01

aldi1, did they say why?

[aldi1] 30/10/2015 16:26

well the 16.8 buy was me this morning but i had to cancel the trade as redmayne bentley cant trade this for my sipp. very disappointing.....

[barrywhit] 30/10/2015 10:34

Been away, good update, all looking positive going forward. IDS-ISYS now has 36 Allergens optimised so nearly at the magic 40 required for the platform..
CD4 problem identified, so a matter of time to resolve. India refit complete. Revenues steady and the options package positive...and we know the share price when it moves it moves quickly as majority of shares are tightly held...

[longshanks] 30/10/2015 09:58

Really poor form by Barclays. I can't understand why they would ever remove a stock from their trading list unless for example there was a conflict of interest. I have often found it takes time for newly listed companies to become available - which is understandable, but to remove shares is quite perverse.I use iWeb who are also amazing value at £5/trade.Good to see you monitoring Pug. It is all a matter of balance in a portfolio, I guess: potential, as we know, can take years to become realised. Spreading the pot gives you more spins of the wheel. I think ODX is really undervalued; it could start generating decent cash flow within two years. That is illustrated by the recent options granted with a vesting price of 50p: the shares could reach £1+ in three years time IMO.

[rivaldo] 30/10/2015 09:40

Nice buying this morning, the latest at 16.8p - having a good effect too.

Given the forecast 1.3p EPS this year - and the cash pile - the blue sky projects for CD4 and allergens are in the share price for nothing, so with the positive signs in this week's trading update ODX looks pretty cheap to me at these prices.

OT : agreed re SCE having multibagger potential, but of course it's dependent on that "gamechanger" news coming through.

[pugugly] 30/10/2015 09:03

rivaldo/longshanks:- Intersting to see you here - A very slow burner with chartwise a slow drift down from floatation back in 2006 - Turnover increased by less than 10% in the last 4 years though pretax and margins have improved.

Brokers are optimistic but then they usually are - especially house brokers and Edison are paid for their work - Hummmmmmmmmm. Probably better upside opportunity in putting more funds into SCE even after the recent gains That is provided at least one of the game changers comes to pass.

[weatherman] 27/10/2015 18:13

I've raised a complaint as well pointing out I may have to leave Barclays if they do this without giving warning. The price has moved 0.75p since I wanted to trade. Perhaps they should compensate for not providing the full service. I don't think it has anything to do with the company, but I would think is about Barclays costs for offering a service on ODX.

[rivaldo] 27/10/2015 15:15

Weatherman, I've just experienced the same problem with Barclays.

Having phoned up to complain, and then moved up the chain to a "manager", the only explanation is that it's a "business decision". Barclays refuse to explain any further, but did note to me that this now applied to a number of other stocks. I asked for a list, but they were unable to provide such a list.

On enquiring I was told this "business decision" was taken on October 21st, so it doesn't appear to be related to any specific ODX announcements.

I've phoned ODX and spoken to the FD to let him know - he was of course unaware and extremely concerned. He's going to get Finncap on Barclays' case.

It's appalling imo. Barclays are execution-only, not advisory. What gives them the right to decide which stocks their customers can or cannot invest in?

I advised Barclays that this is going to cause a real stink for them with investors if they've applied this across a number of companies, and have asked them to get their Client Relations team to contact me pronto.

It's an effing disgrace!

[p1nkfish] 27/10/2015 09:05

stock available at AJ Bell.

[weatherman] 27/10/2015 08:53

Barclays stockbrokers are refusing to place a buy for me, as they have stopped all purchase trades on this stock. Any one know why?

[hyperboreus] 26/10/2015 08:16

I too am more than happy to pick up stock at these levels longshanks and have been steadily adding of late and will continue to do so whilst it remains sub 15p

[hyperboreus] 26/10/2015 08:14

Patience is required with CD4 but it would appear the new Chief Operating Officer is understandably keen on ensuring his option package targets are met sooner rather than later and is clearly intent on galvanising resources and minds at Omega:

Colin King, Chief Operating Officer of the Company commented: "Since coming on board on 3 August, I have been encouraged by the scale of opportunities in the core business units and believe we can exploit these in a more aggressive manner. As a result of this we have undertaken a review of each unit and are now in the process of developing a 3 to 5 year business plan with accelerated growth the key objective."

[longshanks] 26/10/2015 07:52

The market was worried about them running out of cash. Cash flow is healthy, they have ongoing growth in their core products and turnover was ahead 11% on a constant currency basis.

They have had a successful trial in Spain of the iSYS product which means we are likely within a year of having commercial sales.

The new manufacturing facility in Pune will be delivering tangible benefits to the bottom line, too, within the year.

The CD4 product has taken time to get right - but we are very close to that now and there is obvious confidence that the iterative cycle on testing is now very short.

I am happy to buy stock with all these factors in place, I think the market will like these factors too.

[longshanks] 26/10/2015 07:21

Very good, positive, trading update. Don't see any cash call on the horizon so this should rerate quite sharply from here on out.

[barrywhit] 20/10/2015 12:55

Hi P1nkfish and Leeds,

Hope you are both well......

[leedslad001] 20/10/2015 12:02

Morning all hope u are all well? Not long to results now Monday morning maybe

[p1nkfish] 20/10/2015 11:32

I have been adding here on weakness.

Would be no surprise to find Sneller has been adding but no need to notify as between % levels.

His last big buy was June at a higher price.

ODX is a very promising opportunity. I don't trade but did buy/sell in the past 12 months as the price ran up. Most recent purchases are how holds for 2-5 all being well.

Good luck barry. These are better management than selfish fatso at you know where.

[longshanks] 20/10/2015 08:21

Unlikely to be directors as they are in a closed period ahead of announcing results I believe. More likely is some corporate paper shuffle for tax purposes by brokers and/or large investors while the price is low.

[barrywhit] 19/10/2015 13:04

Afternoon All,

250k delayed trade just gone through........Looks like a buy?, Director?

[longshanks] 14/10/2015 11:47

Where do you get 0.6p for FY2015 EPS?

In the final results they give the EPS as 1.3p so the FY2016 forecast just shows (as expected) negligible impact of Allersys or Visitect and/or change in the core business.

They have an unused banking facility of £1m but yes cash does look to be rather tight and I guess it all comes down to what the cash flow forecast is.

Putting £0.9m into a new Visitect manufacturing facility when they already have capacity of upto 2.5m test kits in house would indicate that they have sourced some additional funds - perhaps with a substantial grant underlying it.

[boonkoh] 14/10/2015 11:01

1.3p EPS forecast for FY2016 looks a bit steep, considering FY2015 was around 0.6p. Looking at the timelines, CD4 test doesn't seem likely to launch before the end of the current financial year, so assuming no revenue contribution. Cash is also a bit tight at less than £2m, with cash burn this year due to continued trials and R&D expenses and manufacturing ramp up from CD4.Overall its looking like after the upcoming trading update, broker forecasts will be trimmed for FY2016, and cash situation will be tighter, so maybe a small fundraising is on the cards.